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Headache is a very commonly encountered symptom in pregnancy and is usually due to primary headache disorders which are
benign in nature. It can however be quite debilitating for some women who may need therapeutic treatment of which there
are several options safe to use in pregnancy. It is equally important though to recognise that headache may be a sign of serious
underlying pathology. This paper aims to provide a clinically useful guidance for diﬀerentiation between primary and secondary
headaches in pregnancy. The primary headache disorders and their management in pregnancy are explored in depth with brief
overviews of the causes for secondary headaches and their further investigation and management.
1.Introduction
Headache is a very common condition and the commonest
reasonforreferraltoaneurologist[1].Mostheadacheshavea
female predominance with peak incidence in the second and
thirddecades,peakprevalencebeinginthefourthdecade[2–
6]. More than 80% of women in the reproductive age group
experience headache at some stage making it a common
symptom encountered during pregnancy [7].
Most headaches in pregnancy are benign and may cause
a trivial inconvenience to quite signiﬁcant debilitation.
However, headache in pregnancy may herald the onset of
life-threatening conditions such as eclampsia, stroke (haem-
orrhagic or thrombotic), and Arterio-Venous malformations
(AVMs).
So is headache in pregnancy just a “nuisance”o rc o u l d
it be a “new sense” heralding the onset of a potentially life-
threatening pathological process? The challenge is to identify
the women who need further investigations in order to avoid
signiﬁcant morbidity and/or mortality.
Classiﬁcation. Headaches in pregnancy may be classiﬁed as
follows.
Benign, for example, migraine, tension-type head-
ache,cluster headaches,analgesic-overuseheadaches,
and so forth.
Pathological, from an underlying pathology, for
example, a vascular event (haemorrhage or throm-
bosis) or raised intracranial pressure (ICP) such as in
brain tumours and benign intracranial hypertension.
The International Headache Society (IHS) has published a
comprehensive classiﬁcation system for headaches—The
International Classiﬁcation of Headache Disorder (ICHD)
(see Table 1)[ 8].
2.Primaryor Benign Headaches inPregnancy
2.1. Migraine. A primary headache disorder deﬁned by the
IHS as headache with particular features—usually unilateral,
often throbbing, and associated with nausea and sensitivity
to light, sound, and head movement [8] .I ti sc l a s s i ﬁ e di n2
ways: migraine without aura (70%) and migraine with aura
(30%) with the absence or presence of associated visual or
neurologic phenomena called “aura” discriminating them.
Auracanprecedetheheadache,occurduringitorafterwards.2 Obstetrics and Gynecology International
Table 1: International Classiﬁcation of Headache Disorder (ICHD).
Part I: the primary headaches
(1) Migraine —with or without aura
(2) Tension-type headaches
(3) Cluster headache and other trigeminal autonomic cephalalgias
(4) Other primary headaches
Part II: the secondary headaches
(1) Headache attributed to head and/or neck trauma such as domestic violence, MVA
(2) Headache attributed to cranial or cervical vascular disorder— hypertension, subarachnoid haemorrhage
(3) Headache attributed to nonvascular intracranial disorder—raised intracranial pressure, meningitis
(4) Headache attributed to a substance or its withdrawal —illicit drug use such as cocaine, alcohol or medication overuse headache
(5) Headache attributed to infections
(6) Headache attributed to disorder of homeostasis—hypoglycaemia, hypoxia
(7) Headache or facial pain attributed to disorder of cranium, neck, eyes, ears, nose, sinuses, teeth, mouth or other facial
or cranial structures—trigeminal neuralgia, Bell’s palsy
(8) Headache attributed to psychiatric disorder
Part III: Cranial neuralgias central and primary facial pain and other headaches
(1) Cranial neuralgias and central causes of facial pain
(2) Other headache, cranial neuralgia, central or primary facial pain
It is thought to result from a reduction in cerebral blood ﬂow
due to neuronal dysfunction rather than ischaemia.
Migraine is common, prevalence 12–15% in the western
world [9]. It is three times more common in females than
males in the postpubertal group [2, 9] while, prepuberty the
sex ratio is 1:1 [10]. In females, the highest prevalence is
during the childbearing years with peak (27%) at age 41.
About 70% of migraineurs have a positive family history so
genetic factors probably play a role in its onset.
2.1.1. Pathophysiology of Migraine. The pathophysiology of
migraine headaches is poorly understood with no one theory
fully accounting for their varied presentations and symp-
tomatology. The headache of migraine occurs from vasodi-
latation or oedema of mainly extracranial and meningeal
arteries, with stimulation of perivascular nerve endings
that stimulates the trigeminal system which in turn causes
headache.
Release of vasoactive substances and complex interplay
between several other neurotransmitters is thought to play
a role: the inhibitory neurotransmitters, which decrease at
headache onset like endorphins, serotonin (5-HT), and
gamma amino butyric acid (GABA), and the excitatory
neurotransmitters, which increase during headache episode
like norepinephrine and dopamine. These changes in neuro-
transmitters cause dilatation of meningeal blood vessels.
Serotonin depletion can induce migraine and selective
serotonin agonists such as the triptans can alleviate it [11].
Migraine pathology occurs in brain structures such as the
trigeminal pain pathway, brainstem nuclei, cerebral vas-
culature, thalamus and the primary sensory cortex [11–13].
Migraine with Aura occurs from a combination of
neuronal disturbance and vascular dysfunction. Initially,
abnormal neuronal activity in the hypothalamic and limbic
systemsleadstotheprodromalsymptomslastingafewhours
to a few days [14]. These may be neurological, psychological,
or constitutional with 60% of migraineurs recognizing these
as markers of an oncoming attack [15]. This prodrome is
followed by aura—a wave of neuronal activation then inhibi-
tionemanatingfromafocuslikelyintheoccipitalcortex[16]
accompanied by a decrease in cerebral blood ﬂow leading to
clinically apparent visual, sensory or motor phenomena with
occasional brain stem and language disturbances. As aura
subsides, a marked increase in blood ﬂow occurs, in part
due to serotonin-induced midbrain stimulation [17]. This
is accompanied by a headache which is generally unilateral,
throbbing, and associated with nausea and vomiting in up to
30% of patients [18] although it may be bilateral. Also seen
issensoryexcitabilitywithsymptomexacerbationbyphysical
activity, light, sound or smell. The postdrome follows which
less well characterised, cerebral blood ﬂow is returning to
normalduringthistime.Clinicallythemigraineurfeelstired,
lethargic, and depressed but occasionally has euphoria.
Migraine without aura seems to lack the phase of
reduction in cerebral blood ﬂow hence the absence of aura.
2.1.2. Eﬀect of Pregnancy on Migraine. Fluctuations in oe-
strogen levels are known to inﬂuence migraines with high
oestrogen levels improving and falling levels deteriorating
the symptoms [7] this being particularly apparent during
the menstrual cycle with headache most likely to occur 2
days before or after the onset of menses [19]. A number
of studies have shown that the high stable oestrogen levels
in pregnancy improve migraine symptoms with up to 11%
of women reporting improvement in the ﬁrst trimester,
rising to 53% in the second and 79% in the third trimester
particularly women with menstrual migraine [7, 20, 21].
Conversely, others have found that the greatest improvement
in headaches is seen in the ﬁrst trimester and migraines that
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[7]. Postpartum, the oestrogen levels rapidly fall explaining
the exacerbation seen postpartum with up to 34% of women
suﬀering a relapse in the ﬁrst week rising to over 55%
withinamonth[21].Breastfeedingprovidessomeprotection
probably relating to stable though low oestrogen levels.
Hormonal inﬂuences may not be the only reason for
symptom improvement in pregnancy and analgesic eﬀects
of increased β-endorphins, and emotional changes may
account for some cases of improvement.
4–8% of women experience deterioration in their symp-
toms migraine with aura less likely to improve for rea-
sons that remain largely unexplained [22] though platelet
hyperaggregation is suggested. This may also account for the
increased risk of ischaemic stroke associated with migraine
with aura. Some women develop migraine for the ﬁrst time
in pregnancy leading to a diagnostic dilemma.
2.1.3. Eﬀect of Migraine on Pregnancy. Migraines with or
without aura, in general, do not seem to have any adverse
eﬀects on the outcome of pregnancy [23]; however, an
increasing body of evidence suggests an association between
migraine, preeclampsia, and eclampsia [24–27]. A recent
case control study [28] found that a history of migraine
was associated with a 1.8-fold increased risk of preeclampsia
(95%CI1.1–2.7).Olderwomen(≥30years)whendiagnosed
with migraine were at the highest risk (OR 2.8, 95% CI 0.8–
9.0). Overweight migraineurs had a 12-fold increased risk of
preeclampsia as compared to lean migraineurs (95% CI 5.9–
25.7).
There is an increased risk of stroke in pregnant women
[29, 30] and migraine particularly migraine with aura is an
independent risk factor for stroke, particularly among young
women [31]. However, not many studies have focused on
the risk of pregnancy-related stroke in migraineurs. James et
al. [32] reviewed data from the Nationwide Inpatient Sam-
ple relative to pregnancy-related discharges and found an
overall risk of pregnancy-related stroke of 34.2 per 100,000
deliveries. The strongest associations for stroke were mi-
graine with an OR of 16.9 (95% CI 9.7–29.5) and throm-
bophilia with an OR of 16.0 (95% CI 9.4–27.2).
2.1.4. Management of Migraine in Pregnancy. The major
concern in the management of the pregnant patient with
migraines, as with other medical disorders, is the eﬀect
of both the medication and the disease on the fetus.
As most women with migraines improve after the ﬁrst
trimester, they can usually be managed with reassurance and
nonpharmacological measures such as ice packs, massage,
relaxation, and biofeedback [33, 34]. A holistic approach
yields the best results with avoidance of triggers, lack of
sleep, and psychological stress. A lifestyle of regular exercise,
regular meal times, and regular sleep patterns helps; later by
reducing 5-HT-mediated neuronal activation [35].
Somewomen,however,continuetohavedebilitatingand
intractable headaches associated with nausea and vomiting
with the attendant risk of dehydration. These women require
pharmacological treatment.
The pharmacological treatment of migraines can be
divided into abortive treatment—to manage an acute attack
and prophylactic treatment—to prevent recurrence. Adju-
vant therapy with antiemetics is commonly needed during
acute attacks (see Table 2).
2.2. Abortive Therapy. Paracetamol is the ﬁrst-line treatment
for short-term relief of mild-to-moderate pain in pregnancy
due to its safety in pregnancy. Its mechanism of action
is poorly understood; however, it is an eﬀective analgesic
reducing the intensity though not the duration of pain in an
acute attack of migraine [36].
Opioids modulate pain by suppressing activity in ascend-
ing nociceptive pathways and altering central perception
by reducing primary nociceptive aﬀerent activity [37].
Codeine phosphate is most commonly used and works
better in combination with paracetamol [38]; however, daily
opioid use should be avoided to prevent the development
of medication-overuse headache. There is no increase in
the incidence of birth defects in women given codeine
during pregnancy despite earlier studies suggesting this [39]
although transient symptoms of neonatal withdrawal may be
seen after regular exposure in the third trimester.
Antiemetics are extremely useful adjuncts for the asso-
ciated symptoms such as nausea and vomiting that can be
equally disabling as the headache. Also, some medications
used to treat migraines can cause nausea. Metoclopramide
is particularly useful as it reduces the gastric atony seen with
migraine, increases small intestine peristalsis and enhances
the absorption of coadministered medications [40]. Its
antidopaminiergic eﬀect may also help prevent migraine
headache if used in the prodromal phase [15]o rt oa b o l i s h
established headache if used later. Other antiemetics such as
chlorpromazine, prochlorperazine, and promethazine, can
all be safely used in pregnancy [41].
Aspirin and other NSAIDs control migraine pain
by inhibiting cyclooxygenase activity and thus reducing
prostaglandin production [42]. Analgesic doses of aspirin
and other NSAIDs have been shown to be safein the ﬁrst and
second trimesters of pregnancy [43]; however, chronic expo-
sure or exposure to high doses after 30 weeks of pregnancy is
associated with premature closure of ductus arteriosus and
restriction of renal blood ﬂow in some foetuses [44, 45].
Their use has also been linked to increased risk of necrotising
enterocolitisandintraventricularhaemorrhageinpotentially
viable preterm babies [46]. Use of high doses of NSAIDs
in the third trimester has been linked with antepartum and
postpartum haemorrhage [47], and hence the use of aspirin
and other NSAIDs should be avoided in the third trimester
and when a very preterm birth is anticipated.
To obviate the potentially harmful eﬀects of high doses
of NSAIDs, they can be given at lower doses in combination
with paracetamol to achieve a synergistic eﬀect, frequently
in combination with caﬀeine, which is thought to potentiate
their eﬃcacy and increase the speed of onset of pain relief.
Caﬀeine is also an analgesic through its action as a cerebral
vasoconstrictorandmayalsoincreasepaintolerancethrough
a poorly understood mechanism [48, 49]. Daily intake of up4 Obstetrics and Gynecology International
Table 2: Drugs commonly used for treatment and/or prophylaxis of migraine and their FDA rating and fetomaternal eﬀects.
Drug FDA rating Maternal eﬀects Fetal eﬀects Compatible with
breastfeeding
Paracetamol B Medication overuse None Yes
Opioids B/C Overuse/dependence
Constipation ??cleft palate/inguinal hernia Yes
Aspirin C Increased risk bleeding Narrowing of ductus arteriosus Yes
NSAIDs B/D Inhibition of implantation
Premature closure of ductus
arteriosus
Restriction of renal blood ﬂow
NEC and IVH in preterm foetuses
Yes
Triptans C Limited evidence possible increased
miscarriage ?Preterm birth and IUGR ??
Antiemetics B/C None None Yes
Caﬀeine B Overuse/withdrawal headache NoneHigh doses—miscarriage,
IUGR Yes
Ergot alkaloids X Uterine hypercontractility
Reduced placental perfusion
Miscarriage
Fetal compromise
Intestinal atresia
No
Beta blockers B/C None ?IUGR, fetal bradycardia Yes
Antiepileptics C/D None Malformations Yes
Antidepressants B/C None High doses—neonatal depression,
irritability, spasms, or convulsions Caution
to 300mg caﬀeine appears to be safe in pregnancy; intake
beyond this may be associated with miscarriage and fetal
growth restriction [50].
Ergotderivativesarehighlyeﬀectivefortreatmentofacute
migraine attacks by blocking 5-HT receptors and causing
widespread vasoconstriction. However, they cause uterine
hypertonicity and vascular disruption increasing the risk of
miscarriage [51]. There have been reports of a small number
of babies born with injuries consistent with tissue ischaemia
after ergot use in pregnancy [52]. The use of ergot and its
derivatives is contraindicated in pregnancy.
Triptans such as sumatriptan, rizatriptan, and naratrip-
tan abort migraine attacks by antagonising 5-HT receptors
in the midbrain. The safety of triptans during pregnancy
has yet to be established although data from a number of
cohort studies, drug company surveillance, and prospective
pregnancy registries are reassuring and conﬁrm that inad-
vertent exposure to sumatriptan during pregnancy is not
associated with adverse fetal eﬀects [53–56]. However, the
work to date is not suﬃciently powered to detect a small
increaseinfetalanomalies,soalthoughwomeninadvertently
exposed to triptans should be reassured, triptans should
be avoided during pregnancy. Two studies have suggested a
link between exposure to sumatriptan in second and third
trimesters and fetal growth restriction and preterm birth
although the results were statistically insigniﬁcant [54, 55].
There is limited data available for other triptans and the
continued use of these agents is not recommended during
pregnancy unless no other treatment is eﬀective.
Magnesium sulphate intravenously has recently been
shown to be an eﬃcient, safe and welltolerated agent in the
treatment of migraine, more eﬀective than placebo in
reducing or abolishing pain and in reducing the associated
symptoms of nausea and vomiting [57, 58]. As its maternal
and fetal safety proﬁle is well established from its use in
preeclampsia-eclampsia, magnesium sulphate may prove to
be a useful agent for management of acute migraine attacks
in pregnancy. Further studies are needed, however, before its
routine clinical use can be advocated.
Dexamethasone has been used sporadically in severe
migraine unresponsive to other therapies [59]; however
its routine use in pregnancy is not justiﬁed as there is
little reliable published evidence on its eﬃcacy and possible
adverse maternal and fetal side eﬀects [60].
2.3. Prophylactic Therapy. As recurrent attacks of migraine
canbeextremelydebilitating,prophylactictherapyshouldbe
considered if there are more than 3 acute attacks per month.
Low-dose aspirin is suggested as ﬁrst-line agent for mi-
graine prophylaxis in pregnancy given its safety established
by extensive study during pregnancy for prophylaxis of
preeclampsia. One small trial of 28 pregnant women with
frequent or severe attacks of migraine taking low-dose
aspirin (75mg) for migraine prophylaxis showed subjective
improvement in 22 women [61]. The ability of aspirin to
counteract the platelet activation of pregnancy is thought to
be the rationale behind its use for this indication.
Beta blockers prevent cerebral arterial vasodilatation
thereby reducing the frequency and severity but not the
duration of migraine attacks [62, 63]. Beta blockers have
been suggested to be associated with fetal growth restriction
[64] which is thought to be a class eﬀect and is possibly dose
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or metoprolol is suggested. As an alternative, labetolol
(combined alpha and beta blocker) has been used with some
success in pregnancy [65].
Antidepressants such as amitriptyline or mirtazapine
reduce the severity, frequency and duration of migraine
attacks by a mechanism involving central inhibition of
5-HT and histamine receptors [62, 66]. Amitriptyline is
particularly eﬀective in women for reasons which are not
clear [62]. Low doses of amitriptyline (10–50mg at night)
appear to be adequate and safe for migraine prophylaxis.
At higher doses used for depression, tachycardia, irritability,
muscle spasms, and convulsions have been reported in
neonates.
Antiepilepticssuch as sodium valproate are being increas-
ingly used for migraine prophylaxis outside of pregnancy;
however a signiﬁcant increase in fetal malformations pre-
cludes its use in pregnancy.
Other drugs—Although data on pitozifen are limited,
there are no reports of adverse outcomes during pregnancy.
Others such as verapamil, although safe, have very limited
eﬃcacy while methysergide is contraindicated in pregnancy.
3. Tension-Type Headaches (TTHs)
TTHs are the most common headache types, lifetime prev-
alence 78% with a female: male ratio of 3:1. They are char-
acterized by a generalized pressure or tightness in the head
whichisunaﬀectedbyactivity.DiagnosisofTTHsisbasedon
history and clinical examination after excluding alternative
explanation for the symptoms. Their diﬀerentiation from
migraine is usually straightforward due to the episodic
nature and accompanying symptoms of migraine. It may,
however, be diﬃcult to distinguish these from secondary
headaches.
3.1. Pathophysiology of TTH. This is even less clear than
the pathophysiology of migraines. The mechanism seems to
be similar to migraine with the involvement of the same
neuroanatomic structures such as the trigeminal nucleus.
Serotonin and endorphins are again thought to play a major
role [67]. TTHs would be expected to improve during
pregnancy as these neurotransmitters are inﬂuenced by
female hormones, and this is supported by clinical studies
although improvement is less marked than that seen with
migraines [3, 7, 68].
3.2. Eﬀect of Pregnancy on TTHs. Studies evaluating the
course of TTHs in pregnancy are few and far between and
show conﬂicting results. In one study, 67% of TTH patients
showed no change in symptoms, 28% reported improve-
ment, and 5% worsening [3], while in another study 50%
women with TTH reported improvement with only 33%
of migraineurs reporting the same [23]. Sample sizes of
these studies are too small to draw reliable conclusions or
to identify prognostic factors which might help in predicting
which patients would improve in pregnancy and which not.
3.3. Eﬀect of TTH on Pregnancy. There does not appear to
be any association between TTH and adverse pregnancy out-
comes.
3.4. Management of TTHs in Pregnancy. As psychological
factors and musculoskeletal stresses in pregnancy have been
implicated in the worsening of TTH in pregnancy, nonphar-
macologicaltherapies suchasrelaxation, stressmanagement,
and biofeedback are highly eﬃcacious for the management
of TTHs in pregnancy with no side eﬀect to mother or
fetus [69, 70]. Pharmacological treatment is similar to
that of migraines with paracetamol and NSAIDs being the
mainstayofacutetreatmentwiththesameguidingprinciples
as discussed in the treatment of migraines. Prophylactic
treatment is seldom indicated and only if headaches are
occurring more than 2 to 3 days per week.
4.ClusterHeadaches (CHs)
It is severe primary headache disorder accompanied with
autonomic symptoms [8] such as ipsilateral nasal conges-
tion and rhinorrhoea, lacrimation, conjunctival hyperaemia,
facial diaphoresis, palpebral oedema, and Horner’s syn-
drome. CHs are characterised by attacks of excruciating,
penetrating pain typically short in duration (5–180 minutes)
with no aura. The pain is classically periorbital but may
radiate to other areas of the face and neck. Headache
frequency ranges from once every other day to as often as
severaltimesaday[71].Triggersincludealcohol,vasodilator,
drugs and sleep apnoea-induced hypoxaemia.
CH is relatively rare (prevalence 0.06 to 0.4%) even more
so during pregnancy as this is one of the few headache
disorders with a male predominance, male: female ratio 9:1
[72, 73]. Female hormones seem to have little inﬂuence on
CH [74, 75].
4.1.PathophysiologyofCHs. Littleisknownaboutthepatho-
genesisofCHs.TheperiodicityofCHshasbeenattributedto
hypothalamic hormonal inﬂuences with the suprachiasmatic
nuclei and the posterior hypothalamic grey matter being the
mostlikelysiteofpathology[76,77].ThetypicalpainofCHs
is thought to originate at the pericarotid/cavernous sinus
complex which receives sympathetic and parasympathetic
input from the brain stem, explaining the occurrence of
autonomic phenomena during an attack [78]. The inﬂuence
of hypoxaemia and hypocapnia in CHs is still unclear.
4.2. Pregnancy and CH. Due to the relative rarity of CH in
women and its episodic nature, there are few studies of the
eﬀectofpregnancyonCH,theresultsofwhichareequivocal.
Overall, pregnancy does not seem to have a major impact on
CH and vice versa [74, 75].
4.3. Management of CH in Pregnancy. In the nonpregnant
patient, 100% oxygen by face mask, corticosteroids, triptans
and ergot alkaloids are the mainstay of abortive treatment
for CH. CH may be particularly diﬃcult to treat during
pregnancy. 100% oxygen is safe to use and eﬀective in about6 Obstetrics and Gynecology International
70% of attacks [79]. Corticosteroids are compatible with
use in pregnancy and lactation, but triptans should be used
sparingly while ergot derivatives are contraindicated during
pregnancy. Prophylaxis is rarely indicated with verapamil
and corticosteroids being the most commonly used prophy-
lactic medications [71].
5. Medication-OveruseHeadache
(AnalgesicRebound Headache)
It is important to remember this entity which describes
the headache-precipitating tendency following frequent or
long-term use of analgesics. Medication overuse may be
due to a physical or psychological dependency with the
prime quest being pain relief and is present in about
40% of migraineurs. Provoking agents include ergotamine,
triptans, simple analgesics, opioids and combination anal-
gesics. Management includes patient education, explanation
of the diagnosis, and gradual withdrawal of the causative
agent which improves symptoms with majority of patients
reverting to their primary headache disorder within two
months.
6.Secondary orPathological Headaches
inPregnancy
Pregnant women presenting with new onset headache in
the pregnancy or those with atypical features such as focal
neurological signs, papilloedema, or seizures should be
urgently evaluated for underlying secondary causes and
a neurology opinion sought. The causes for secondary
headaches in pregnancy include preeclampsia-eclampsia,
stroke (haemorrhagic or ischaemic), cerebral venous throm-
bosis, benign (idiopathic) intracranial hypertension (BIH),
pituitaryapoplexymeningitis/encephalitis,postpartumcere-
bral angiopathy, and postpartum dural puncture headache.
6.1. Preeclampsia-Eclampsia. Headache is a symptom of
severe preeclampsia and occurs in about 75% of women
with eclampsia where it always precedes the seizure [80].
Headache in preeclampsia-eclampsia can be bitemporal,
frontal, occipital, or diﬀuse with most women describing
the pain as pulsating although a feeling of pressure or
sharp pain is described by some. A characteristic feature is
its progressive nature and failure to respond to over-the-
counter (OTC) remedies. It can be associated with visual
changes such as blurred vision, scotomata, or bright ﬂashing
lights [81]. The pathophysiology is largely unknown, but
two aetiologies are suggested: (1) marked vasospasm in the
cerebral vasculature in response to elevated systemic blood
pressure resulting in ischaemia and (2) vasoconstriction
of cerebral vasculature followed by reﬂex vasodilatation
leading to overdistension, extravasation of ﬂuid and cerebral
oedema. Normally cerebral autoregulation protects against
sudden changes in blood pressure; however, when systolic
blood pressure exceeds 150mmHg, the autoregulation starts
to fail and hypertensive encephalopathy may develop [82].
6.2. Stroke in Pregnancy. S t r o k eo c c u r si n3 . 5t o8 . 6w o m e n
per 100,000 deliveries [82, 83]. One study has shown a rate
of ischaemic stroke of 11 per 100,000 deliveries and intrac-
erebral haemorrhage of 9 per 100,000 deliveries, greatest risk
of both in the postpartum period [83]. Headache occurs
with acute stroke in 18% to 38% of patients, more so in
haemorrhagic than in ischaemic stroke [84, 85]. Epidemio-
logical studies have identiﬁed a relative risk of stroke during
pregnancy as 2.4 or an excess risk of 8.1 strokes per 100,000
pregnancies [29]. The mortality following pregnancy-related
stroke is estimated at 10–13% being disproportionately
higher in black women, older women, and those with no
antenatal care [86, 87].
6.3. Ischaemic Stroke. Risk factors for ischaemic stroke in
pregnancy include African-American ethnicity, age over
35 yrs, caesarean delivery, known medical disorders such
as hypertension, diabetes, sickle cell disease, vasculitis,
antiphospholipid syndrome or thrombophilia, heart disease
and SLE, smoking, alcohol and recreational drug abuse
(particularly cocaine), multiple gestation, and multipar-
ity. Complications of pregnancy such as preeclampsia-
eclampsia, hyperemesis, and disturbances in electrolyte and
ﬂuid balance are other signiﬁcant risk factors. In one
study, 47% of non-haemorrhagic pregnancy-related strokes
occurred in the context of preeclampsia-eclampsia [83].
Diagnosis is by MRI or CT to conﬁrm and also to
diﬀerentiate haemorrhage from infarction. Treatment de-
pends on the underlying cause, and antiplatelet therapy
and/or anticoagulation may be needed. The safety of acute
thrombolysis in pregnancy remains unproven, but there are
case reports of its use with no adverse eﬀects [88–90].
6.4. Haemorrhagic Stroke. This is very rare in women of
child-bearing age outside pregnancy but almost as common
as ischaemic stroke during pregnancy. Eclampsia accounts
for 44% of intracerebral haemorrhagic strokes in pregnancy
[83]. In one study, of 34 cases of pregnancy-related stroke, 13
were haemorrhagic with 7 being subarachnoid haemorrhage
(SAH)[91].SAH,resultingfromaneurysmsorarteriovenous
malformations (AVM), accounts for 3% of all strokes [92].
Outside pregnancy, the ratio of aneurysm to AVM is 7:1,
but, in pregnancy, relatively more cases are due to AVMs
(ratio 1:1). A rare cause of intracerebral haemorrhage
in pregnancy is choriocarcinoma, metastases of which are
frequently haemorrhagic so may present in pregnancy with
an intracerebral or SAH [93].
Risk of haemorrhage from an AVM in previously asymp-
tomatic women is around 3.5% [94]. AVMs can dilate under
eﬀect of oestrogen. Pregnancy does not seem to increase the
riskofﬁrsthaemorrhagefromanAVM;hence,itwouldseem
reasonable to defer treatment of an AVM that has not bled
until after delivery; however, if diagnosed before pregnancy,
pregnancy should be deferred until after treatment. In
patientswhopresentwithableedduringpregnancy,decision
for interventional treatment is more diﬃcult with currently
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is no advantage of a caesarean section over vaginal delivery;
however, it is prudent to endure adequate pain relief with
epidural analgesia and to curtail the length of the second
stage of labour.
The overall risk of recurrence of stroke in a subsequent
pregnancy is small.
6.5. Cerebral Venous Thrombosis (CVT). uncommon (inci-
dence 1:10,000) with most cases occurring postpartum
with a high mortality rate [95]. Underlying pathology is
thought to be the hypercoagulability of pregnancy; however,
a thrombophilia screen is recommended to rule out any
additional prothrombotic tendency. One report showed a
link between puerperal CVT and Protein S deﬁciency [96].
Presenting symptoms include headache, seizures, altered
consciousness, and neurological deﬁcits with signs of raised
ICP. The gold standard for diagnosis is venous angiography
MRI. Management includes hydration, anticonvulsants, and
anticoagulants. Although ﬁrm evidence for the beneﬁt of
anticoagulation is lacking, a number of studies during
pregnancyhavesuggestedimprovementinsurvivalfollowing
anticoagulation [97].
6.6.Benign(Idiopathic)IntracranialHypertension(BIH). Be-
nign intracranial hypertension or pseudotumour cerebri is
a unique syndrome seen mostly in obese young women,
and pregnancy has been identiﬁed as a risk factor [98].
The volume of cerebrospinal ﬂuid (CSF) is increased due
to unknown reasons resulting in raised ICP leading to
headaches and papilloedema. Symptoms of BIH usually
increase during pregnancy [99].
Raised ICP may also result from brain tumours;h o w e v e r ,
these are rare during pregnancy and usually present with
raised ICP, neurological deﬁcits, or seizures rather than
headaches. Pregnancy is associated with accelerated growth
of some tumours such as meningiomas and pituitary adeno-
mas [100].
6.7.PituitaryApoplexy. Pituitaryapoplexyduringpregnancy
is a rare but serious event with signiﬁcant morbidity and
possible mortality, if not timely recognised. It is a clinical
syndrome consisting of sudden onset of severe headache,
altered consciousness, vomiting, visual disturbances, and
ophthalmoplegia thought to be caused by haemorrhage
and/or infarction in the pituitary gland, although exact
pathophysiology remains unknown. Its occurrence in preg-
nancy is rare with only a few cases reported. Usually a pre-
existing pituitary adenoma is present although it may be the
ﬁrstsignofapituitarytumour.Oestrogenscausehyperaemia
of the hypophysis and could therefore contribute to the
risk of apoplexy in pregnancy [101]. Treatment consists of
replacement of the deﬁcient hormones especially glucocorti-
coids, close surveillance, and transsphenoidal surgery [102]
but some advocate conservative management especially in
pregnancy with surgery reserved for cases where there is
no spontaneous improvement or worsening of visual im-
pairment and/or consciousness [103].
6.8. Meningitis/Encephalitis. Any infection of the head/neck
can present as headache but the diagnosis is likely to be
suggested from the accompanying symptoms.
6.9. Postpartum Cerebral Angiopathy (PPCA). It is cerebral
dysregulation syndrome aﬀecting large- and medium-sized
cerebral arteries, it may be associated with haemorrhagic or
ischaemic stroke usually within the ﬁrst week postpartum.
Although the pathophysiology is unclear, it is thought to
be an inﬂammatory process such as vasculitis or transient
vasospasm seen as areas of stenosis and ectasia in multiple
intracranial vessels on cerebral angiography [104]. Clinical
picture typically occurs in women aged 20–50 years with
abrupt onset of severe “thunderclap” headaches, seizures,
and focal neurological deﬁcit [105]. Several medications, for
example, ergotamine, triptans and bromocriptine, if given
intra- or postpartum can contribute to its development
by their vasospastic eﬀect on cerebral vasculature [106].
Prompt diagnosis and treatment can prevent fatality. Treat-
ment includes corticosteroids and calcium channel block-
ers such as nimodipine (preferential cerebral vasodilator).
Most events resolve quickly without permanent neurological
deﬁcits.
6.10. Postpartum Dural Puncture Headache (PDPH). PDPH
is a disabling and distressing complication of inadvertent
puncture of dural membrane while performing epidural
analgesia in parturients. Excessive CSF seepage from the
dural tear leads to a fall in CSF pressure and stretching
of meninges manifesting as a headache. Compensatory
intracranial vasodilatation in response to fall in CSF pressure
mayfurtherworsentheheadache.Incidenceofunintentional
dural puncture with epidural needle is around 1% while the
incidence of PDPH following dural puncture with 16–18 G
Tuohy needle is approximately 70%. Common features of
PDPH are:
(i) onset 24–48hrs post dural puncture,
(ii) severe, throbbing headache in the frontooccipital
region which can radiate to neck and shoulders,
(iii) pain exacerbation by head movement and upright
posture, relieved by lying down,
(iv) associated features such as photophobia, nausea,
vomiting, tinnitus, diplopia, hearing loss, dizziness
and VIth cranial nerve palsy may be present.
Reassurance, hydration, simple analgesics, and caﬀeine are
the mainstay of early treatment, while epidural blood patch
(EBP) is the deﬁnitive treatment [107]. Mechanism of action
of EBP is twofold (1) blood in epidural space compresses the
dural sac raising ICP which provides immediate pain relief
and (2) sealing of dural tear by blood clot preventing further
CSF leak. EBP performed after 24 hours in symptomatic
patients has a success rate of 80–90% increasing to 95% after
second EBP. EBP should be avoided in the ﬁrst 24 hours
because of a high failure rate around 70% [108].8 Obstetrics and Gynecology International
Table 3: Warning signs and symptoms—“New Sense.”
(i) New onset headache or change in pattern of chronic headache
(ii) Neurological signs, for example, seizures, focal deﬁcits, gait disturbances, visual changes, slurred speech, and so forth
(iii) Meningeal signs
(iv) Fever
(v) Vomiting
(vi) Headache changing with posture
(vii) Thunderclap onset
(viii) Valsalva headache (headache triggered with Valsalva-type manoeuvres)
(ix) Trauma
6.11. A Practical Approach to Management of a Pregnant
Woman Presenting with Headache. Pregnant women with a
headache can be categorized into three groups:
(1) women with a known primary headache disorder
presenting with their typical headache,
(2) women with a known primary headache disorder
presenting with a headache diﬀerent in character
from their typical headache,
(3) women presenting with a new onset headache.
Even though migraine is known to change character
in pregnancy, the ﬁrst scenario is likely to be benign;
however, in the other two, a high index of suspicion
should be maintained for secondary causes and neurologists
involved in the care. We suggest the following approach to
management.
Thoroughhistory—Acarefulhistorycanbediagnosticin
most cases. Particular note should be given to “red ﬂags” or
“warning signs”—“NEW SENSE”: Table 3.
Clinical examination:
a thorough general examination with vital
signs,
a full neurological examination including oph-
thalmologic examination for papilloedema.
Investigations:
urinalysis,
full blood count,
blood Biochemistry including liver function
tests,
coagulation proﬁle.
Additional Investigations:
radiological imaging:
CT and/or MRI without contrast,
lumbar puncture:
if fever/neck rigidity/raised white cell count,
thunderclap headache with negative CT to
r/o subarachnoid bleed,
r/o benign intracranial hypertension.
7. Conclusion
Most headaches in pregnancy are benign and due to primary
headache disorders being largely treatable with reassurance,
nonpharmacological remedies, and simple analgesics. A high
index of suspicion for serious underlying pathology should
be maintained if atypical features are identiﬁed on history
and/or clinical examination especially if a woman presents
with a headache for the ﬁrst time in her pregnancy in
ordertoinstitute timely managementandpreventsigniﬁcant
morbidity and mortality.
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